竞品公开数据不足，强生与传奇生物撤回ASH对比研究摘要

Core Insights - The retraction of the research abstract focuses on the treatment of multiple myeloma, aiming to compare data from Carvykti's Cartitude-1 and Cartitude-4 trials with the iMMagine-1 trial data of the BCMA-targeted CAR-T therapy anito-cel developed by Gilead and Arcellx [1] Group 1: Research and Development - The core reason for the retraction was the limited public data available for anito-cel, as stated by Alan Bash, head of Carvykti's business, during the Q3 earnings call [1] - The decision to retract was made in consensus with the research authors, with an emphasis on the hope to share complete data in the future [1] Group 2: Market Impact - Leerink Partners noted on November 4 that there are persistent differences in key prognostic variables among trial patients, such as prior use of anti-CD38 antibodies and resistance to last-line treatment, making direct comparison of data challenging [1] - The ASH annual meeting is a top academic conference in the hematology field, and research presentations at this event often influence industry perceptions of drug value [1] - Although the retraction does not affect the current clinical application of Carvykti, it highlights the data acquisition challenges in head-to-head studies within the CAR-T therapy field, adding uncertainty to the competition between the two similar drugs [1]